President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Patient PortalAdult ClinicPediatricsEye CareMake an AppointmentBillingInfo for Healthcare Professionals
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCommercialization and VenturesJoslin Institute for Technology Translation (JITT)
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

Doug Melton, Ph.D.

Dr. Melton's laboratory works in the general area of regenerative medicine. They focus all of their work on diabetes, aiming to turn pluripotent stem cells into pancreatic insulin-producing beta cells and to reconstruct human type 1 diabetes (T1D) in a humanized mouse.  Much of Dr. Melton's research focuses on deriving human pluripotent stem cells, both ES and iPS cells, for use as a starting material.  The Melton lab uses biological and chemical screening approaches to identify the signals that can direct these cells into insulin-secreting pancreatic beta cells. In addition, they use these same molecular, cellular and genetic approaches to make other components implicated in type 1 diabetes.  Specifically, the Melton lab aims to make thymic epithelia and hematopoietic stem cells as the two components that educate and execute immune attacks.  All of these components will be put into a “living test tube” in an attempt to reconstruct human type 1 diabetes.  The living test tube is a humanized mouse, a NOD/SCID/IL2Rgamma mutant mouse.

Page last updated: October 01, 2016